Cromos Pharma, where the patients are

AstraZeneca

AstraZeneca selects Dotmatics platform

Monday, July 29, 2013 01:25 PM

AstraZeneca’s Neuroscience Innovative Medicines Unit (iMed) has selected Dotmatics’ cloud based informatics platform as its research data management solution. The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, fully integrated chemistry and biology ELN and project management to enable scientists, collaborators and partners to instantly interact with the same data regardless of location and time zone.

More... »

CRF Health eCOA webinar series

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »


Vivus board appoints new chairman, CEO

Wednesday, July 24, 2013 03:00 PM

Biopharmaceutical company Vivus’ board of directors has appointed Michael Astrue chairman and Anthony Zook chief executive officer.

More... »

AstraZeneca, Tufts collaborate on neuroscience research

Thursday, July 18, 2013 09:00 AM

AstraZeneca, Tufts University's School of Medicine and Sackler School of Graduate Biomedical Sciences are collaborating to establish a team of postdoctoral researchers who will work to advance understanding of diseases and disorders of the brain, including Alzheimer's disease, Parkinson's disease, neurodevelopmental and autism spectrum disorders. As part of a three-year agreement, the new team will conduct laboratory research into biological targets of interest in neuroscience.

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

AstraZeneca inks cancer collaboration

Wednesday, July 10, 2013 12:27 PM

AstraZeneca has entered into an agreement with the University of Cambridge and Cancer Research U.K. for a two-year collaboration on three preclinical and clinical oncology projects. This agreement aims to advance cancer research through the study of tumor mutations and new investigational therapies in prostate, pancreatic and potentially other cancers.

More... »

Blackfield signs fourth pharmaceutical partnership

Wednesday, July 10, 2013 12:09 PM

Germany-based researcher Blackfield is collaborating with AstraZeneca. Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models to support one of AZ’s oncology drug development programs.

More... »

Optibrium, AstraZeneca sign deal for global software license

Tuesday, July 9, 2013 11:29 AM

AstraZeneca has signed an agreement to license software developer Optibrium's StarDrop software. StarDrop and the ADME-QSAR and Auto-Modeller modules will be deployed globally to AstraZeneca's researchers.

More... »

Roche, AstraZeneca launch early research data-sharing consortium

Tuesday, July 2, 2013 01:24 PM

Roche and AstraZeneca are collaborating to share early research data related to drug design to further accelerate discovery of high-quality compounds with an increased chance of clinical success.

More... »

Sarah Cannon, AstraZeneca partner for oncology

Tuesday, July 2, 2013 12:53 PM

Sarah Cannon Research Institute (SCRI) and AstraZeneca will collaborate to develop new AstraZeneca oncology compounds. The companies will work on molecular profiling to classify tissue based on genetic profiles for the purpose of treating cancers and predicting response to therapy.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs